U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.85
    -0.50 (-2.44%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.5422%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.4074%)
     
  • BTC-USD

    19,221.26
    -69.51 (-0.36%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

  • Oops!
    Something went wrong.
    Please try again later.
·16 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Quotient Limited
Quotient Limited
  • Financial Position

    • Amended Secured Notes: Reduces the company’s cash obligations by approximately $93 million over the next 36 months

    • Announces Public Equity Offering: Improving liquidity runway

    • FY 2022 Revenue of $38.5 Million

    • $83.2 million in cash and investments as of March 31, 2022

  • MosaiQ™ Solution

    • Commercial Execution:

      • Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customers

      • Tenders: Actively engaged in Immunohematology (IH) donor tenders;
        20 European IH donor tender submissions expected in the next 18 months

      • Distribution Network: 9 international agreements in place and expanding global distribution network

    • Transfusion Diagnostics: Extended Serological Disease Screening (SDS) microarray panel continues to progress towards EU commercial launch in calendar year 2023

    • Clinical Diagnostics: Partnership with Theradiag to accelerate time to the development of Autoimmune microarray with optimized costs; Will expand access to $2 billion autoimmune IVD specialty market with MosaiQ; Expected entry into EU and US markets in calendar year 2023

    • Scientific & Medical Affairs: Successful KOL event held providing expert validation in real-world settings; Innovator’s Circle community is comprised of 8 experts to enable better patient care; Launch of Company’s international research program, Investigator Initiated Research (IIR), with Centre Pasteur in Cameroon (CPC)

JERSEY, Channel Islands, June 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2022 key financial results and provided an update on recent business developments and key upcoming milestones.

“I am deeply proud of the tremendous progress we have achieved at Quotient during my first year as CEO,” said Manuel O. Mendez, Chief Executive Officer of Quotient. “We received European CE mark approval of the MosaiQ Extended IH microarray in March, and we are announcing a financing with key equity and debt restructuring to strengthen our balance sheet and provide the necessary capital to improve our liquidity runway and advance our commercial and clinical execution strategy. We have a talented and experienced management team to lead us through this period of exciting growth and shareholder value creation for our company.”

Financial Position:

The Company reported cash, cash equivalents and investments of $83.2 million at the end of March 2022 that will allow the Company to continue to drive the expansion of the MosaiQ menu forward and continue the commercialization efforts following the receipt of CE Mark for the Expanded Immunohematology microarray. The recently announced financing strengthens the Company’s cash position and provides additional financial and operational flexibility and an improved liquidity runway.

MosaiQ Solution

Commercial Execution: 

Extended Immunohematology (IH) Launch: The Company recently secured $1.4 million of orders in the first quarter of fiscal year 2023 for its recently CE marked Extended IH MosaiQ solution.

Tenders: The Company will continue to participate in upcoming IH tenders in Europe and expanding distribution outside of the US. There are over 20 IH tenders which have been identified by the Company and which it intends to pursue across Europe when available for submission over the next 18 months. Quotient remains active in preparing for new tenders in the rest of the world where CE marking is accepted.

Distribution: In addition, the Company is focused on expanding its distribution footprint across the major international geographies. The Commercial team has signed nine international agreements with distributors.

Transfusion Diagnostics:

Immunohematology (IH) Microarray: In March, the Company received CE Mark for the MosaiQ Extended Immunohematology (IH) Microarray. The receipt of CE Mark allows the Company to commercialize the microarray for use with the Company’s MosaiQ instrument across the European Union and other CE Mark recognizing geographies.

The Company’s MosaiQ platform offers an all-in-one, fully automated, high-performance solution in blood-testing laboratories and other settings. The IH microarray offers extended phenotyping, Antibody Screening and Antigen Typing, including ABO forward and reverse grouping. Laboratories and clinicians may use the platform to generate comprehensive characterization of blood donor samples through a single test procedure.

Serological Disease Screening (SDS) Microarray: The Company has made advances on the Extended SDS panel and continues to expect to submit an application in the EU for CE mark in the second half of calendar year 2022. The Company expects an EU commercial launch and a US FDA BLA submission in the first half of calendar year 2023.

Clinical Diagnostics:
The recently announced Theradiag partnership serves as a key step to introduce the multimodal, multiplexed MosaiQ solution to various clinical diagnostic specialty segments with the aim of enabling clinical labs to simplify the complexity of diagnostic algorithms and accelerate standards of care. The first application covered by their new collaboration will be a solution for Connective Tissue Diseases (CTD). The autoimmune IVD pathway to market has a tighter turnaround time due to different regulatory requirements and is at a lower cost than blood transfusion. The Company estimates that autoimmune diagnostics would provide an additional $2 billion addressable market opportunity for Quotient’s MosaiQ solution.

Scientific & Medical Affairs:
The Company hosted a successful key opinion leader (KOL) webinar (available on the Quotient website) with Dr. Christophe Martinaud (MD, PhD), on the current landscape and unmet needs within blood grouping and donor disease screening, providing expert validation for the MosaiQ solution.

To further strengthen scientific and medical synergies, a total of eight members are participating in the MosaiQ Innovator’s Circle initiative. The goal of the initiative is to create a community of experts at institutions across the world who focus on transfusion medicine and clinical diagnostics. Members partner with Quotient to create innovation and evidence generation to improve patient care and laboratory efficiencies.

In addition, Quotient has established an Investigator Initiated Research (IIR) program open to all healthcare professionals who wish to study the clinical and economic impact of the MosaiQ system.
The Company recently announced an international partnership with Centre Pasteur du Cameroon (CPC) for the IIR program. This partnership will provide Quotient’s R&D team with rare HIV samples and will sponsor young scientists studying infectious diseases in Africa.

Additionally, the Company established a new Scientific Advisory Board relating to Autoimmunity and Allergy and has published a white paper focused on how increasing phenotype-matched blood provided to hospital patients is expected to make transfusion medicine safer and more effective.

Fiscal Fourth Quarter Financial Results:
The Alba by Quotient reagent business generated product sales of $9.8 million in the fourth quarter of FY 2022, up 2% from the quarter ended March 31, 2021. OEM sales increased by 3% and sales to direct customers and distributors were up 9% vs. Q4 FY2021. In the quarter ended March 31, 2022, gross margin on product sales was at 39% compared to the gross of margin of 46% reported in the quarter ended March 31, 2021.

Key revenue and profit results are summarized below (expressed in thousands, except percentages)

 

 

 

 

 

 

 

 

 

Quarter Ended
March 31,

 

 

Year Ended
March 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

(in thousands, except percentages)

 

 

 

 

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales - OEM customers

 

$

6,654

 

 

$

6,470

 

 

$

25,653

 

 

$

23,224

 

Product sales - direct customers and distributors

 

 

3,132

 

 

 

2,870

 

 

 

12,539

 

 

 

11,287

 

Product sales - MosaiQ

 

 

-

 

 

 

240

 

 

 

91

 

 

 

1,276

 

Other revenues

 

 

-

 

 

 

58

 

 

 

231

 

 

 

7,592

 

Total revenue

 

$

9,786

 

 

$

9,638

 

 

$

38,514

 

 

$

43,379

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales from standing purchase orders (%)

 

 

69

%

 

 

64

%

 

 

66

%

 

 

67

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

$

3,795

 

 

$

4,447

 

$

 

14,944

 

 

$

23,305

 

Gross profit as a % of total revenue

 

 

39

%

 

 

46

%

 

 

39

%

 

 

54

%

Gross margin on product sales (%)

 

 

39

%

 

 

46

%

 

 

38

%

 

 

44

%

Operating loss

 

$

(26,865

)

 

$

(28,458

)

$

 

(103,827

)

 

$

(82,697

)

Total operating expenses for the quarter decreased by $2.2 million or 7% compared to the fourth quarter of the prior fiscal year. This decrease is driven primarily by a reduction in executive management transition payments compared to the prior year.

Capital expenditures totaled $0.6 million in the quarter ended March 31, 2022, compared with $0.6 million in the quarter ended March 31, 2021.

Interest expense for the quarter increased by $2.9 million compared to Q4 of FY 2021. The higher interest expense recognized in the current period is driven by the issuance of our Convertible Notes in fiscal year 2022 and an increase in our estimated royalty liability as a result of an increase in projected sales over the periods subject to the agreement.

As of March 31, 2022, Quotient had $83.2 million in cash and investments and $233.3 million of debt and $8.7 million in restricted cash.

Of the $83.2 million in cash and investments, $18.1 million relates to investments held in Credit Suisse Supply Chain funds. In Q4, we determined that a further impairment of $1.0 million was required related to litigation costs incurred by Credit Suisse which Credit Suisse communicated would be deducted from investor recoveries. Our holdings in one of the Credit Suisse funds has been classified as a long-term investment as of March 31, 2022.

Outlook for the Fiscal Year Ending March 31, 2023

  • The Company expects total sales in the current fiscal year will be in the range of $39 million to $42 million compared to $38.5 million in FY 2022.

  • Capital expenditures for fiscal year 2023 are expected to be in the range of $5 million to $10 million.

  • The Company estimates that cash used for operations for fiscal year 2023 will be in the range of $6.5 million to $7.5 million per month (excluding debt service cost and capital expenditures).

The accompanying consolidated financial statements have been prepared on a basis which assumes that Quotient will continue as a going concern. However, the Company has incurred net losses from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $725.0 million as of March 31, 2022. The Company expects to include a disclosure within its Annual Report on Form 10-K in respect of certain conditions concerning the Company’s overall liquidity position that raise substantial doubt about its ability to continue as a going concern.

Conference Call:
Quotient will host a conference call on June 24th, 2022, at 8:00 a.m. Eastern Time to provide a business update. Participants may access the call by dialing 1-877-407-0784 in the U.S. or +1-201-689-8561 outside the U.S. The access code is 13729874. The conference call will be webcast live on the Company’s website at www.quotientbd.com or by using the following webcast link.

A replay of this conference call will be available through July 8th, 2022, by dialing 1-877-407-0784 in the U.S. or +1-201-689-8561 outside the U.S. The access code is 13729874.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. The MosaiQ solution, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. The MosaiQ solution is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, and deliver significant workflow improvements and operational cost savings to laboratories around the world. Quotient’s operations are based in Switzerland, Scotland, US, and the UAE.

The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of full year fiscal 2023 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Investor Relations, ir@quotientbd.com; +41 22 545 52 26 

 

Quotient Limited 
Condensed Consolidated Statements of Comprehensive Loss 
(in thousands, except share and per share amounts)

 

 

 

Year ended March 31,

 

 

 

2022

 

 

2021

 

Revenue:

 

 

 

 

 

 

Product sales

 

$

38,283

 

 

$

35,787

 

Other revenues

 

 

231

 

 

 

7,592

 

Total revenue

 

 

38,514

 

 

 

43,379

 

Cost of revenue

 

 

(23,569

)

 

 

(20,074

)

Gross profit

 

 

14,944

 

 

 

23,305

 

Operating expenses:

 

 

 

 

 

 

Sales and marketing

 

 

(11,023

)

 

 

(9,849

)

Research and development, net of government grants

 

 

(58,691

)

 

 

(53,727

)

General and administrative expense:

 

 

 

 

 

 

Compensation expense in respect of share options and management equity incentives

 

 

(6,951

)

 

 

(4,984

)

Other general and administrative expenses

 

 

(42,107

)

 

 

(37,442

)

Total general and administrative expense

 

 

(49,058

)

 

 

(42,426

)

Total operating expense

 

 

(118,771

)

 

 

(106,002

)

Operating loss

 

 

(103,827

)

 

 

(82,697

)

Other income (expense):

 

 

 

 

 

 

Interest expense, net

 

 

(31,954

)

 

 

(29,804

)

Other, net

 

 

11,612

 

 

 

2,723

 

Other income (expense), net

 

 

(20,342

)

 

 

(27,081

)

Loss before income taxes

 

 

(124,169

)

 

 

(109,778

)

Provision for income taxes

 

 

(961

)

 

 

(1,254

)

Net loss

 

$

(125,130

)

 

$

(111,032

)

Other comprehensive income (loss):

 

 

 

 

 

 

Change in fair value of effective portion of foreign currency cash flow hedges

 

$

(355

)

 

$

582

 

Unrealized loss on short-term investments

 

 

(186

)

 

 

(898

)

Foreign currency gain (loss)

 

 

6,007

 

 

 

(2,057

)

Provision for pension benefit obligation

 

 

2,941

 

 

 

447

 

Other comprehensive income (loss), net

 

 

8,407

 

 

 

(1,926

)

Comprehensive loss

 

$

(116,723

)

 

$

(112,958

)

Net loss available to ordinary shareholders 
   - basic and diluted

 

$

(125,130

)

 

$

(111,032

)

Loss per share - basic and diluted

 

$

(1.23

)

 

$

(1.21

)

Weighted-average shares outstanding
   - basic and diluted

 

 

101,910,562

 

 

 

91,637,966

 


 

Quotient Limited 
Condensed Consolidated Balance Sheets 
(In thousands)

 

 

 

March 31, 2022

 

 

March 31, 2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

65,059

 

 

$

45,673

 

Short-term investments

 

 

2,626

 

 

 

65,999

 

Trade accounts receivable, net

 

 

6,272

 

 

 

5,323

 

Inventories

 

 

22,036

 

 

 

22,011

 

Prepaid expenses and other current assets

 

 

5,761

 

 

 

4,870

 

Total current assets

 

 

101,754

 

 

 

143,876

 

Restricted cash

 

 

8,744

 

 

 

9,024

 

Long-term investments

 

 

15,467

 

 

 

 

Property and equipment, net

 

 

33,242

 

 

 

39,071

 

Operating lease right-of-use assets

 

 

29,411

 

 

 

22,011

 

Intangible assets, net

 

 

520

 

 

 

619

 

Deferred income taxes

 

 

123

 

 

 

255

 

Other non-current assets

 

 

4,728

 

 

 

4,956

 

Total assets

 

$

193,989

 

 

$

219,812

 

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

4,524

 

 

$

4,659

 

Accrued compensation and benefits

 

 

8,503

 

 

 

12,343

 

Accrued expenses and other current liabilities

 

 

15,729

 

 

 

14,009

 

Current portion of long-term debt

 

 

 

 

 

24,167

 

Current portion of operating lease liability

 

 

3,535

 

 

 

3,446

 

Current portion of finance lease obligation

 

 

537

 

 

 

835

 

Total current liabilities

 

 

32,828

 

 

 

59,459

 

Long-term debt, less current portion

 

 

233,313

 

 

 

145,059

 

Derivative liabilities

 

 

13,515

 

 

 

 

Operating lease liability, less current portion

 

 

28,753

 

 

 

20,907

 

Finance lease obligation, less current portion

 

 

388

 

 

 

445

 

Deferred income taxes

 

 

1,988

 

 

 

1,152

 

Defined benefit pension plan obligation

 

 

4,777

 

 

 

6,896

 

7% Cumulative redeemable preference shares

 

 

22,525

 

 

 

21,475

 

Total liabilities

 

 

338,087

 

 

 

255,393

 

Commitments and contingencies

 

 

 

 

 

 

Shareholders' equity (deficit):

 

 

 

 

 

 

Ordinary shares (nil par value) 102,611,397 and 101,264,412 issued and outstanding at March 31, 2022 and March 31, 2021 respectively

 

 

540,736

 

 

 

540,813

 

Additional paid in capital

 

 

46,399

 

 

 

38,116

 

Accumulated other comprehensive loss

 

 

(6,191

)

 

 

(14,598

)

Accumulated deficit

 

 

(725,042

)

 

 

(599,912

)

Total shareholders' equity (deficit)

 

 

(144,098

)

 

 

(35,581

)

Total liabilities and shareholders' equity (deficit)

 

$

193,989

 

 

$

219,812

 


 

Quotient Limited 
Condensed Consolidated Statements of Cash Flows 
(In thousands)

 

 

 

Year ended March 31,

 

 

2022

 

 

2021

OPERATING ACTIVITIES:

 

 

 

 

 

Net loss

 

$

(125,130

)

 

 

$

(111,032

)

Adjustments to reconcile net loss to net cash provided by operating activities operating activities:

 

 

 

 

 

 

Depreciation, amortization and loss on disposal of fixed assets

 

 

7,417

 

 

 

 

8,354

 

Share-based compensation

 

 

6,156

 

 

 

 

4,984

 

Increase in deferred lease rentals

 

 

659

 

 

 

 

726

 

Swiss pension obligation

 

 

669

 

 

 

 

1,054

 

Amortization of deferred debt issue costs and discount

 

 

11,020

 

 

 

 

12,965

 

Impairment of investments

 

 

970

 

 

 

 

2,285

 

Change in fair value of derivative instruments

 

 

(19,395

)

 

 

 

 

Accrued preference share dividends

 

 

1,050

 

 

 

 

1,050

 

Provision for income taxes

 

 

961

 

 

 

 

1,254

 

Net change in assets and liabilities:

 

 

 

 

 

Trade accounts receivable, net

 

 

(1,143

)

 

 

 

568

 

Inventories

 

 

(165

)

 

 

 

(475

)

Accounts payable and accrued liabilities

 

 

3,418

 

 

 

 

(3,410

)

Accrued compensation and benefits

 

 

(3,735

)

 

 

 

4,549

 

Other assets

 

 

(1,796

)

 

 

 

(454

)

Net cash used in operating activities

 

 

(119,044

)

 

 

 

(77,582

)

INVESTING ACTIVITIES:

 

 

 

 

 

Increase in short-term investments

 

 

(4,500

)

 

 

 

(87,247

)

Realization of short-term investments

 

 

51,425

 

 

 

 

134,936

 

Purchase of property and equipment

 

 

(2,851

)

 

 

 

(4,240

)

Purchase of intangible assets

 

 

 

 

 

 

 

Net cash from investing activities

 

 

44,074

 

 

 

 

43,449

 

FINANCING ACTIVITIES:

 

 

 

 

 

Repayment of finance leases

 

 

(713

)

 

 

 

(633

)

Proceeds from issuance of long-term debt

 

 

104,222

 

 

 

 

 

Debt issuance costs

 

 

(3,732

)

 

 

 

 

Repayment of long-term debt

 

 

(12,083

)

 

 

 

 

(Cost of) proceeds from issuance of ordinary shares and warrants

 

 

(76

)

 

 

 

80,881

 

Net cash generated from financing activities

 

 

87,618

 

 

 

 

80,248

 

Effect of exchange rate fluctuations on cash and cash equivalents

 

 

6,458

 

 

 

 

(4,358

)

Change in cash and cash equivalents

 

 

19,106

 

 

 

 

41,757

 

Beginning cash and cash equivalents

 

 

54,697

 

 

 

 

12,940

 

Ending cash and cash equivalents

 

$

73,803

 

 

 

$

54,697

 

Supplemental cash flow disclosures:

 

 

 

 

 

Income taxes paid

 

$

 

 

 

$

 

Interest paid

 

$

19,008

 

 

 

$

17,529

 

Reconciliation of cash, cash equivalents and restricted cash:

 

 

 

 

$

 

Cash and cash equivalents

 

$

65,059

 

 

 

$

45,673

 

Restricted cash

 

$

8,744

 

 

 

$

9,024

 

Total cash, cash equivalents and restricted cash

 

$

73,803

 

 

 

$

54,697